Welcome to our dedicated page for Thermo Fisher Scientific news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fisher Scientific stock.
Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific (NYSE: TMO) has completed the sale of its microbiology business to Astorg, a pan-European private equity firm, for total consideration of approximately $1.075 billion. The deal consideration consists of cash and a $50 million seller note.
According to Thermo Fisher Scientific, the divested microbiology business provides antimicrobial susceptibility testing and culture media solutions used in clinical, pharmaceutical and food safety testing. The business generated $645 million in revenue in 2025 and was previously part of the company’s Specialty Diagnostics segment.
Thermo Fisher Scientific (NYSE:TMO) reported second quarter 2026 revenue of $11.99 billion, up 10% year over year, including 5% organic revenue growth. GAAP diluted EPS rose 9% to $4.68, while adjusted EPS increased 13% to $6.03.
GAAP operating income grew 14% to $2.09 billion, with GAAP operating margin improving to 17.4% from 16.9%. Adjusted operating income increased 15% to $2.74 billion, driving an adjusted operating margin of 22.8% versus 21.9%. Free cash flow reached $1.68 billion, up from $1.11 billion.
By segment, revenues were $2.82 billion in Life Sciences Solutions, $1.85 billion in Analytical Instruments, $1.21 billion in Specialty Diagnostics, and $6.69 billion in Laboratory Products and Biopharma Services. The company announced the divestiture of its microbiology business and repurchased $1.0 billion of stock during the quarter.
Thermo Fisher Scientific (NYSE:TMO) announced that its board authorized a quarterly cash dividend of $0.47 per common share. The dividend is payable on October 15, 2026 to shareholders of record as of September 15, 2026, providing a scheduled cash return to eligible investors.
Thermo Fisher Scientific (NYSE:TMO) will release its Q2 2026 earnings before the market opens on Thursday, July 23, 2026, followed by an earnings conference call at 8:30 a.m. ET.
The live webcast, earnings release, and replay will be available in the Investors section of the company website.
Thermo Fisher Scientific (NYSE:TMO) will showcase next-generation Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at ASMS 2026 in San Diego. These platforms combine high-sensitivity instrumentation with AI-driven analytics to support multiomics research, biopharma characterization and complex drug development workflows from discovery through regulatory-ready data.
Thermo Fisher Scientific (NYSE:TMO) declared a new quarterly cash dividend. The Board authorized a $0.47 per common share dividend, payable on July 15, 2026 to shareholders of record as of June 15, 2026.
Thermo Fisher Scientific (NYSE:TMO) used its 2026 Investor Day to outline its role in a $255 billion served market, its industry leadership, and its AI-enabled growth strategy.
The company targets 7% long-term organic revenue CAGR and low-teens adjusted EPS growth, supported by innovation, its PPI Business System, and disciplined capital deployment combining strategic M&A and shareholder returns.
Terrestrial Energy (Nasdaq: IMSR) appointed Tyler Gronbach as Vice President of Investor Relations and Public Relations, effective May 7, 2026. Gronbach will report to CEO Simon Irish and lead IR and PR as the company advances commercialization of its Integral Molten Salt Reactor (IMSR).
The hire follows Terrestrial Energy's Nasdaq listing and emphasizes expanded engagement with institutional investors, sell‑side analysts and financial media during IMSR commercialization.
Thermo Fisher Scientific (NYSE: TMO) will hold its 2026 Investor Day on Wednesday, May 20, 2026 at 9:00 a.m. ET in New York City. Presentations will be given by senior management and conclude with a live Q&A.
A live webcast and a replay will be available via the Investors section of the company website.
Thermo Fisher Scientific (NYSE: TMO) agreed to sell its microbiology business to Astorg for approximately $1.075 billion, including a $50 million seller note.
The unit generated $645 million revenue in 2025, sits in Specialty Diagnostics, and the deal is expected to close in H2 2026, subject to customary conditions and regulatory approvals. The company expects the transaction to be dilutive to adjusted EPS by $0.15 in the first full year after close.